MannKind

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MannKind and other ETFs, options, and stocks.

About MNKD

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501.

CEO

Michael E. Castagna

CEOMichael E. Castagna

Employees

592

Employees592

Headquarters

Danbury, Connecticut

HeadquartersDanbury, Connecticut

Founded

1991

Founded1991

Employees

592

Employees592

MNKD Key Statistics

Market cap

1.09B

Market cap1.09B

Price-Earnings ratio

-48.33

Price-Earnings ratio-48.33

Dividend yield

—

Dividend yield—

Average volume

6.06M

Average volume6.06M

High today

$3.81

High today$3.81

Low today

$3.48

Low today$3.48

Open price

$3.75

Open price$3.75

Volume

4.29M

Volume4.29M

52 Week high

$6.51

52 Week high$6.51

52 Week low

$2.23

52 Week low$2.23

Stock Snapshot

As of today, MannKind(MNKD) shares are valued at $3.53. The company's market cap stands at 1.09B, with a P/E ratio of -48.33.

On 2026-06-01, MannKind(MNKD) stock traded between a low of $3.48 and a high of $3.81. Shares are currently priced at $3.53, which is +1.3% above the low and -7.5% below the high.

MannKind(MNKD) shares are trading with a volume of 4.29M, against a daily average of 6.06M.

During the past year, MannKind(MNKD) stock moved between $2.23 at its lowest and $6.51 at its peak.

MNKD News

TipRanks 16h

MannKind price target raised to $11 from $10 at Wells Fargo

Wells Fargo raised the firm’s price target on MannKind (MNKD) to $11 from $10 and keeps an Overweight rating on the shares. The firm cites Afrezza’s approval in...

Nasdaq 2d

MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market

MannKind (NASDAQ:MNKD) said the U.S. Food and Drug Administration has approved Afrezza for pediatric patients with diabetes ages 6 and older, expanding the inha...

CBS News 3d

Pennsylvania teen part of trial as FDA approves needle-free insulin for kids with diabetes: "It's pretty cool" - CBS News

...

Analyst ratings

88%

of 8 ratings

Buy

87.5%

Hold

12.5%

Sell

More MNKD News

Simply Wall St 3d

MannKind Is Up 10.0% After FDA Drops Afrezza Lung Cancer Trial Requirement – What’s Changed

In late May 2026, MannKind Corporation disclosed that the FDA has released it from a large, long-planned postmarketing lung cancer risk trial for Afrezza, leavi...

TipRanks 4d

MannKind Released From Major Afrezza Trial Obligation

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

Simply Wall St 7d

Is It Time To Reassess MannKind After The Recent Share Price Rebound

Wondering whether MannKind's current share price lines up with its underlying worth, or if the market is mispricing the stock. The stock last closed at US$3.38...

People also own

Based on the portfolios of people who own MNKD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.